Skip to content

Study · Non-randomized trial · 1995

4 results

[Cerebrolysin in treatment of acute ischemic stroke].

Domzał T, Zaleska B

Neurologia i neurochirurgia polska1 May 1995Cited by 3 (Europe PMC)

PMID7566407 (opens in a new tab)PepBankPUB-07566407
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with acute ischemic stroke, recovery occurred in 10 patients treated with Cerebrolysin.

    In plain wordsIn patients with acute stroke, 10 recovered during Cerebrolysin treatment.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableRecovery
    Study

    n: not reported in source

    Outcome group
    Overall treatment effect · Nervous system and cognition
    Studied dose
    15 ml daily · intravenous infusion · 21 daysAs given in this study (human).

    Measurements

    Patients with recovery
    10 patients
    Cerebrolysin

    Source sentences

    Summary
    Recovery in 10 patients and improvement in 3 was obtained and only one patient died.
    2 context sentences
    Summary · context
    In an open clinical trial patients with acute ischaemic stroke in the region of the middle cerebral artery, were treated.
    Summary · context
    Cerebrolysin was administered as intravenous infusion in daily dose of 15 ml during 21 days.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with acute ischemic stroke, improvement occurred in 3 patients treated with Cerebrolysin.

    In plain wordsIn patients with acute stroke, 3 improved during Cerebrolysin treatment.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseImprovement
    Study

    n: not reported in source

    Outcome group
    Overall treatment effect · Nervous system and cognition
    Studied dose
    15 ml daily · intravenous infusion · 21 daysAs given in this study (human).

    Measurements

    Patients with improvement
    3 patients
    Cerebrolysin

    Source sentences

    Summary
    Recovery in 10 patients and improvement in 3 was obtained and only one patient died.
    2 context sentences
    Summary · context
    In an open clinical trial patients with acute ischaemic stroke in the region of the middle cerebral artery, were treated.
    Summary · context
    Cerebrolysin was administered as intravenous infusion in daily dose of 15 ml during 21 days.
  3. 03HumanNon-randomized trialSafety outcome

    One patient with acute ischemic stroke died during Cerebrolysin treatment.

    In plain wordsOne patient with acute stroke died during Cerebrolysin treatment.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableDeath
    Study

    n: not reported in source

    Outcome group
    Mortality · Whole body
    Studied dose
    15 ml daily · intravenous infusion · 21 daysAs given in this study (human).

    Measurements

    Patients who died
    1 patient
    Cerebrolysin treatment in acute ischemic stroke

    Source sentences

    Summary
    Recovery in 10 patients and improvement in 3 was obtained and only one patient died.
    2 context sentences
    Summary · context
    In an open clinical trial patients with acute ischaemic stroke in the region of the middle cerebral artery, were treated.
    Summary · context
    Cerebrolysin was administered as intravenous infusion in daily dose of 15 ml during 21 days.
  4. 04HumanNon-randomized trialEfficacy outcome

    In acute ischemic stroke, therapeutic effects were similar with Cerebrolysin and historical treatment with other drugs.

    In plain wordsIn acute stroke, Cerebrolysin and historical treatment with other drugs had similar therapeutic effects.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedTherapeutic effect versus historical treatment
    Study

    n: not reported in source

    Comparator
    Historical patients treated with other drugs
    Outcome group
    Overall treatment effect · Nervous system and cognition
    Studied dose
    15 ml daily · intravenous infusion · 21 daysAs given in this study (human).

    Measurements

    Historical comparison group size
    108 patients
    Patients treated earlier with other drugs in the therapeutic effect comparison

    Source sentences

    Summary
    Therapeutic effect was similar in all groups.
    3 context sentences
    Summary · context
    The results were compared to the large group of 108 patients treated earlier with other drugs.
    Summary · context
    In an open clinical trial patients with acute ischaemic stroke in the region of the middle cerebral artery, were treated.
    Summary · context
    Cerebrolysin was administered as intravenous infusion in daily dose of 15 ml during 21 days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.